`
`Paper: 51
`Entered: April 26, 2018
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`____________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`____________
`
`
` ARGENTUM PHARMACEUTICALS LLC,
`Petitioner,
`
`v.
`
`
`Trials@uspto.gov
`571-272-7822
`
`
`
`
`
`
`
`
`
`
` CIPLA LTD.,
`Patent Owner.
`____________
`
`Case IPR2017-00807
`Patent 8,168,620 B2
`____________
`
`
`
`Before JAMES T. MOORE, ZHENYU YANG, and
`KRISTI L. R. SAWERT, Administrative Patent Judges.
`
`SAWERT, Administrative Patent Judge.
`
`
`
`Conduct of the Proceeding
`37 C.F.R. § 42.5
`
`
`
`
`
`IPR2017-00807
`Patent 8,168,620 B2
`
`
`
`On April 24, 2018, the Supreme Court held that a final written
`decision under 35 U.S.C. § 318(a) must decide the patentability of all claims
`challenged in the petition. SAS Inst., Inc. v. Iancu, --- S. Ct. -----, 2018 WL
`1914661, at *10 (U.S. Apr. 24, 2018). In our Decision on Institution, we
`determined that Petitioner demonstrated a reasonable likelihood that it would
`establish that at least one of the challenged claims of the ’620 patent is
`unpatentable. Paper 11, 27. Pursuant to the holding in SAS, we modify our
`institution decision to institute on all of the challenged claims and all of the
`grounds presented in the Petition.
`The parties remain free to stipulate to changes in the schedule under
`the terms of the Scheduling Order. If, after conferring, the parties wish to
`otherwise change the schedule or submit briefing not set forth in the
`Scheduling Order, the parties must, within one week of the date of this
`Order, request a conference call with the panel to seek authorization for such
`changes or briefing.
`In consideration of the foregoing, it is hereby:
`ORDERED that, pursuant to 35 U.S.C. § 314(a), we modify our
`institution decision to include review of all challenged claims and all
`grounds presented in the Petition;
`FURTHER ORDERED that Petitioner and Patent Owner shall confer
`to determine whether they desire any changes to the schedule or briefing not
`already permitted under the Scheduling Order, and, if so, request a
`conference call with the panel to seek authorization for such changes or
`briefing within one week of the date of this Order.
`
`
`
`2
`
`
`
`IPR2017-00807
`Patent 8,168,620 B2
`
`
`FOR PETITIONER:
`
`Michael R. Houston
`Joseph P. Meara
`James P. McParland
`FOLEY & LARDNER LLP
`mhouston@foley.com
`jmeara-pgp@foley.com
`jmcparland@foley.com
`
`Tyler C. Liu
`ARGENTUM PHARMACEUTICALS LLC
`tliu@agpharm.com
`
`
`FOR PATENT OWNER:
`
`Dennies Varughese
`Deborah A. Sterling
`Adam C. LaRock
`STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
`dvarughe-PTAB@skgf.com
`dsterlin-PTAB@skgf.com
`alarock-PTAB@skgf.com
`
`
`
`
`
`
`
`3
`
`